Canadian researchers test heart drugs in bid to control deadly heart failure
NCT ID NCT06570473
Summary
This study is testing whether adding one of two existing medications—empagliflozin or ranolazine—to standard care can help control right-sided heart failure in people with pulmonary hypertension. It will enroll 30 adults who have symptoms and evidence of heart strain. The main goal is to see if running a larger future trial with this design is practical, while also checking early signals on heart function and quality of life.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RIGHT VENTRICULAR DYSFUNCTION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
London Health Sciences Centre - University Hospital
NOT_YET_RECRUITINGLondon, Ontario, N6A 5A5, Canada
-
The Ottawa Hospital
NOT_YET_RECRUITINGOttawa, Ontario, K1Y 4E9, Canada
-
The University of British Columbia
NOT_YET_RECRUITINGVancouver, British Columbia, V5Z 1M9, Canada
-
University of Alberta
RECRUITINGEdmonton, Alberta, T6G 2G3, Canada
-
University of Calgary
NOT_YET_RECRUITINGCalgary, Alberta, T1Y 6J4, Canada
Conditions
Explore the condition pages connected to this study.